DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to use the funds to advance its lead drug candidate into clinical development. The company designed the disease-modifying, recombinant protein to treat patients with type 1 diabetes. It modulates the Wnt/β-catenin signalling […]
Dexcom touts more clinical evidence for G6 CGM in Japan
Dexcom (Nasdaq:DXCM) announced that it showcased its Dexcom G6 CGM at the 66th Annual Meeting of the Japan Diabetes Society. G6, now the previous-generation version of the company’s CGM after the launch of the G7, uses a small, wearable sensor. It also features a transmitter, continuously measuring and sending glucose levels wirelessly to a smart […]
Embecta stock rises on Q2 results, reports progress on automated insulin delivery tech
Embecta (Nasdaq:EMBC) shares ticked up today on second-quarter results that topped the consensus forecast, leading to a guidance increase. Shares of EMBC grew 2.1% to $29.52 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.1%. The Parsippany, New Jersey-based diabetes technology […]
Micron Biomedical raises $17M for needle-free drug delivery tech
Micron Biomedical announced today that it added $3 million to its Series A, bringing the total funding to $17 million. Atlanta-based Micron develops dissolvable, microarray-based products to simplify the delivery of drugs and vaccines. J2 Ventures provided the additional $3 million. J2 Ventures Partner Dr. Matt Goldman joins Micron’s board as an observer following the […]
Senseonics stock rises after hours on Street-beating Q1
Senseonics (NYSE:SENS) shares ticked up after hours on first-quarter results that topped the consensus forecast. Shares of SENS rose 1.9% at 66¢ apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.4%. The Germantown, Maryland-based company posted profits […]
Study backs Fitterfly digital therapeutic for diabetes management
New research published in JMIR Diabetes demonstrated the real-world effectiveness of the Fitterfly Diabetes digital therapeutic program. The Fitterfly Diabetes CGM digital therapeutic aims to help in the management of glycemic control for people with type 2 diabetes. Led by Shilpa Joshi, Arbinder Singal, and colleagues, the study demonstrated significant improvements in blood glucose levels and […]
Ascensia expands payment program for Senseonics Eversense E3 CGM
Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM. Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable […]
FDA approves ophthalmic spray from Eyenovia
Eyenovia (Nasdaq:EYEN) announced today that the FDA approved its Mydcombi treatment for use with the Optejet delivery device. New York-based Eyenovia designed Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. It marks the first approved fixed-dose combination of tropicamide and […]
Researchers use skull-implantable ultrasound to help deliver chemotherapy to the brain
Northwestern Medicine shared results from a first-in-human clinical trial for a skull-implantable ultrasound device that supports chemotherapy delivery. The device opened the blood-brain barrier to repeatedly permeate large, critical regions of the human brain. This enabled the delivery of chemotherapy injected intravenously. With the patient awake, a four-minute procedure opens the blood-brain barrier and patients […]
Insulet restructures leadership team to drive growth
Insulet (Nasdaq:PODD) announced today that it reshuffled its organizational structure to accelerate innovation and commercialization. In connection with the reorganization, Bret Christensen, EVP and chief commercial officer, leaves the company today to pursue other opportunities. He agreed to offer consulting services during a transition period. Jim Hollingshead, Insulet’s president and CEO, said Christensen “played an […]
